Most Read Articles
Hannah Wong, 30 Sep 2019

Taisho Pharmaceutical launches Lusefi®, an oral anti-diabetic medication for type 2 diabetes mellitus (T2DM). The medication is expected to lower blood glucose and provide adequate glycaemic control, serving as a new alternative prescription for T2DM. Lusefi, with its active ingredient luseogliflozin hydrate, is available in the form of 2.5 mg and 5 mg tablets.

Tristan Manalac, 19 Nov 2019
Dapagliflozin is able to delay renal disease progression among patients with type 2 diabetes, even in those with normal kidney function, according to a study presented at the recently concluded Kidney Week 2019 of the American Society of Nephrology (ASN 2019).
07 Oct 2019
In pancreatic cancer patients undergoing chemotherapy, the presence of diabetes mellitus is associated with reduced survival and larger tumour, as well as with increased risk of death after treatment, according to a meta-analysis.
09 Oct 2019
In diabetic adults, the presentation of renal disease is heterogenous and involves different mechanisms of action, a new Japan study has found.

Walking before dinner does not translate to 24-h glucose profile improvements

21 Jul 2019

Doing a single bout of walking before dinner has little to no benefits in terms of 24-hour glucose profiles, with the notable exception of a reduction in glucose during the activity itself, according to the results of the E-Paradigm* study.

A total of 80 participants were assigned to two experimental conditions—exercise and nonexercise (control)–separated by 72 hours in a randomized crossover design. Each condition lasted 2 days, during which standardized meals were provided.

Exercise involved 50 minutes of treadmill walking at 5.0 km/h before the evening meal, whereas control consisted of sitting for 50 minutes. Mean glucose during the 24-hour period following exercise (or sitting), measured using continuous glucose monitoring, was the primary outcome.

Of the participants, 73 completed both exercise and control. However, only 63 participants (mean age, 64 years; 54 percent female) observed complied with the standardized diets and had complete continuous glucose monitoring data. Their mean baseline body mass index [BMI] and HbA1c were 30.5 kg/m2 and 51 mmol/mol (6.8 percent), respectively.

Mean 24-h glucose did not improve with exercise vs sitting (0.03 mmol/L, 95 percent CI, –0.17 to 0.22; p=0.778), but individual differences between conditions ranged from –2.8 to 1.8 mmol/L. Likewise, exercise had no significant effect on fasting glucose, postprandial glucose or glucose variability.

There was a notable reduction in glucose concentrations during the 50 minutes of walking vs sitting (–1.56 mmol/L, –2.18 to –0.95; p<0.001).

Researchers pointed out that the E-Paradigm protocol was feasibly implemented across multiple sites and could be implemented in other settings to evaluate responses among individuals with different characteristics or in response to other exercise interventions.

*Exercise-Physical Activity and Diabetes Glucose Monitoring

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Hannah Wong, 30 Sep 2019

Taisho Pharmaceutical launches Lusefi®, an oral anti-diabetic medication for type 2 diabetes mellitus (T2DM). The medication is expected to lower blood glucose and provide adequate glycaemic control, serving as a new alternative prescription for T2DM. Lusefi, with its active ingredient luseogliflozin hydrate, is available in the form of 2.5 mg and 5 mg tablets.

Tristan Manalac, 19 Nov 2019
Dapagliflozin is able to delay renal disease progression among patients with type 2 diabetes, even in those with normal kidney function, according to a study presented at the recently concluded Kidney Week 2019 of the American Society of Nephrology (ASN 2019).
07 Oct 2019
In pancreatic cancer patients undergoing chemotherapy, the presence of diabetes mellitus is associated with reduced survival and larger tumour, as well as with increased risk of death after treatment, according to a meta-analysis.
09 Oct 2019
In diabetic adults, the presentation of renal disease is heterogenous and involves different mechanisms of action, a new Japan study has found.